CME Supplements

Bipolar Depression: Diagnostic Dilemmas to Innovative Treatments

This activity is supported by an independent educational grant from Allergan.

 

Bipolar disorder (BD) is a severe, lifelong disorder associated with high rates of nonrecovery, chronicity, and premature mortality. The actionable opportunity for reducing the morbidity and mortality of BD is to address current unmet needs.

Click here to read the supplement and earn 1 AMA Category 1 Credit TM by learning about these unmet needs, and recent advances and novel strategies for management of depression in BD.


Educational Objectives

  • Discuss the prevalence of bipolar disorder in different psychiatric patients.
  • Describe the different symptoms that occur in children, adolescents, and adults.
  • Use the evidence base, including FDA approval for different treatments, to inform therapy for bipolar depression.
  • Provide details to ensure that physicians consider the potential metabolic profile of antipsychotics when choosing agents.

Click here to read the supplement.

Recommended Reading

Prevalence of developmental disabilities up significantly since 2009
MDedge Psychiatry
Lumateperone for schizophrenia shows safety, tolerability in long-term study
MDedge Psychiatry
Early maternal anxiety tied to adolescent hyperactivity
MDedge Psychiatry
Legislators disagree on new drug-pricing proposal
MDedge Psychiatry
CDC reports most vaping lung disease linked to THC-containing cartridges
MDedge Psychiatry
How does alcohol intake affect dementia risk in older adults?
MDedge Psychiatry
Distinct mood, apathy profiles found in bipolar disorder patients
MDedge Psychiatry
Four genetic variants link psychotic experiences to multiple mental disorders
MDedge Psychiatry
Labeling of medication warnings
MDedge Psychiatry
Medical boards change or consider amending mental health-related licensing questions
MDedge Psychiatry